Evidence map›Paper›PMID 32949546›Full record

ReviewThe Lancet. Neurology2020

Cognitive impairment in multiple sclerosis: clinical management, MRI, and therapeutic avenues.

Ralph H B Benedict, Maria Pia Amato, John DeLuca, Jeroen J G Geurts

2 registry-linked trialsAbstract readCase ReportsReview
PubMed Full text at PMC Publisher
In one paragraph

Review in The Lancet. Neurology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 398 papers, 11 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
398citing papers in PubMed, 11 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05819008 recruitingnot on this mapstarted 2023, after this paper: background citation

Remote Neuropsychological Assessment of Patients With Neurological Disorders and Injuries

TypeobservationalSponsorUmeå UniversityRan2023 to 2027Enrolled350ConditionsTraumatic Brain Injury, Stroke, Multiple Sclerosis, Parkinson DiseaseArmsNeuropsychological Assessment
NCT06198530 naunknown statusnot on this mapstarted 2024, after this paper: background citation

Effectiveness of Nurse-led Clinics Training Program on Mild Cognitive Impairment Patients: a Randomized Controlled Trial Protocol

TypeinterventionalSponsorXuanwu Hospital, BeijingRan2024 to 2025Enrolled96ConditionsMild Cognitive ImpairmentArmscognitive training in NLCs, cognitive training in home, cognitive training in tradition
3 · Its place in the literature

Who cites it

398 citing papers in PubMed, 11 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Rituximab for people with multiple sclerosis.The Cochrane database of systematic reviews · 2025
    Pooled it
  8. Pooled it
  9. Pooled it
  10. Azathioprine for people with multiple sclerosis.The Cochrane database of systematic reviews · 2024
    Pooled it
  11. Pooled it
  12. Trial
  13. Trial
  14. Combined cognitive rehabilitation and neurofeedback therapy: effects on executive function and cognitive flexibility in people with multiple sclerosis.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026
    Trial
  15. Trial
  16. Trial
  17. Trial
  18. Article
  19. Article
  20. Article

338 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Ralph H B BenedictDepartment of Neurology and Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, State University of New York, Buffalo, NY, USA. Electronic address: benedict@buffalo.edu.
Maria Pia AmatoDepartment of Neurology, University of Florence, IRCCS Fondazione Don Carlo Gnocchi, Florence, Italy.
John DeLucaKessler Foundation, West Orange, NJ, USA.
Jeroen J G GeurtsDepartment of Anatomy and Neurosciences, Section Clinical Neuroscience, Amsterdam UMC, Location VUmc, Vrije Universiteit, Amsterdam, Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Multiple sclerosis is a chronic, demyelinating disease of the CNS. Cognitive impairment is a sometimes neglected, yet common, sign and symptom with a profound effect on instrumental activities of daily living. The prevalence of cognitive impairment in multiple sclerosis varies across the lifespan and might be difficult to distinguish from other causes in older age. MRI studies show that widespread changes to brain networks contribute to cognitive dysfunction, and grey matter atrophy is an early sign of potential future cognitive decline. Neuropsychological research suggests that cognitive processing speed and episodic memory are the most frequently affected cognitive domains. Narrowing evaluation to these core areas permits brief, routine assessment in the clinical setting. Owing to its brevity, reliability, and sensitivity, the Symbol Digit Modalities Test, or its computer-based analogues, can be used to monitor episodes of acute disease activity. The Symbol Digit Modalities Test can also be used in clinical trials, and data increasingly show that cognitive processing speed and memory are amenable to cognitive training interventions.

Indexed as

Disease ManagementAdolescentAged, 80 and overCognitive DysfunctionFemaleHumansMagnetic Resonance ImagingMultiple Sclerosis

Identifiers

PMID32949546
PMCPMC10011205

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.